The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 1, 2012, Pages 221-226

  Balko, Justin M ^a   Miller, Todd W ^a   Morrison, Meghan M ^a   Hutchinson, Katherine ^a   Young, Christian ^a   Rinehart, Cammie ^a   Sańchez, Violeta ^a   Jee, David ^b   Polyak, Kornelia ^b,c   Prat, Aleix ^d,e   Perou, Charles M ^d,e   Arteaga, Carlos L ^a   Cook, Rebecca S ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

ErbB3; Mammary epithelial differentiation

Indexed keywords

CYTOKINE; DOXORUBICIN; INTERLEUKIN 6; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR TYROSINE KINASE ERBB3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST EPITHELIUM; BREAST TUMOR; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HISTOLOGY; MAMMARY GLAND; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; TRANSGENIC MOUSE;

ANIMALS; BIOLOGICAL MARKERS; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIAL CELLS; EPITHELIUM; FEMALE; INTERLEUKIN-6; MAMMARY GLANDS, ANIMAL; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; RECEPTOR, ERBB-3;

MUS;

EID: 84856012318     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1115802109     Document Type: Article

References (34)

1. Abd El-Rehim DM, et al. (2004) Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 91:1532-1542. (Pubitemid 39486359)
2. Citri A, Yarden Y (2006) EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 7:505-516. (Pubitemid 44036456)
3. Bazley LA, Gullick WJ (2005) The epidermal growth factor receptor family. Endocr Relat Cancer 12(Suppl 1):S17-S27. (Pubitemid 41395411)
4. Holbro T, Civenni G, Hynes NE (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284:99-110. (Pubitemid 36331969)
5. Carraway KL, III, et al. (1994) The erbB3 gene product is a receptor for heregulin. J Biol Chem 269:14303-14306.
6. Pinkas-Kramarski R, et al. (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467. (Pubitemid 26151185)
7. Kim HH, Vijapurkar U, Hellyer NJ, Bravo D, Koland JG (1998) Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J 334:189-195. (Pubitemid 28420988)
8. Jackson-Fisher AJ, et al. (2008) ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Res 10:R96.
9. Andrechek ER, White D, Muller WJ (2005) Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth. Oncogene 24: 932-937. (Pubitemid 40216100)
10. Jackson-Fisher AJ, et al. (2004) ErbB2 is required for ductal morphogenesis of the mammary gland. Proc Natl Acad Sci USA 101:17138-17143. (Pubitemid 39627787)
11. Long W, et al. (2003) Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development 130:5257-5268. (Pubitemid 37369683)
12. Wiesen JF, Young P, Werb Z, Cunha GR (1999) Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 126:335-344. (Pubitemid 29083971)
13. Erickson SL, et al. (1997) ErbB3 is required for normal cerebellar and cardiac development: A comparison with ErbB2-and heregulin-deficient mice. Development 124:4999-5011. (Pubitemid 28025125)
14. Holbro T, et al. (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100:8933-8938. (Pubitemid 36899201)
15. Wong KK, Engelman JA, Cantley LC (2010) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20:87-90.
16. Qu S, et al. (2006) Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy. Genesis 44:477-486. (Pubitemid 44684994)
17. Gunther EJ, et al. (2002) A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J 16:283-292. (Pubitemid 34195290)
18. Wagner KU, et al. (1997) Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 25:4323-4330.
19. Lim E, et al. (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15:907-913.
20. Lim E, et al. (2010) Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res 12:R21.
21. Prat A, et al. (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68.
22. Fata JE, et al. (2007) The MAPK(ERK-1,2) pathway integrates distinct and antagonistic signals from TGFalpha and FGF7 in morphogenesis of mouse mammary epithelium. Dev Biol 306:193-207. (Pubitemid 46809722)
23. Ewald AJ, Brenot A, Duong M, Chan BS, Werb Z (2008) Collective epithelial migration and cell rearrangements drive mammary branching morphogenesis. Dev Cell 14: 570-581. (Pubitemid 351479940)
24. Whitfield ML, George LK, Grant GD, Perou CM (2006) Common markers of proliferation. Nat Rev Cancer 6:99-106. (Pubitemid 43361542)
25. Harris J, et al. (2006) Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol Endocrinol 20:1177-1187.
26. Oakes SR, et al. (2008) The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev 22:581-586. (Pubitemid 351342431)
27. Zhou J, et al. (2005) Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation. EMBO J 24:635-644. (Pubitemid 40343264)
28. Muraoka-Cook RS, et al. (2011) ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res 71:3941-3951.
29. Herschkowitz JI, et al. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8:R76.
30. Sørlie T, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874. (Pubitemid 32878711)
31. Perou CM, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
32. Asselin-Labat ML, et al. (2008) Delineating the epithelial hierarchy in the mouse mammary gland. Cold Spring Harb Symp Quant Biol 73:469-478.
33. Lindeman GJ, Visvader JE (2010) Insights into the cell of origin in breast cancer and breast cancer stem cells. Asia Pac J Clin Oncol 6:89-97.
34. McBryan J, Howlin J, Kenny PA, Shioda T, Martin F (2007) ERalpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. Oncogene 26:6406-6419. (Pubitemid 47494221)